Tag Archives: Research

Freight Rail Transport in China Business Research Report

Posted on by


San Francisco, CA (PRWEB) July 03, 2013

Current rail freight capacity in China can no longer meet the countrys rapidly increasing transportation demand. As a result, the Chinese government is producing substantial investments into the expansion of the nationwide railway network. By 2020, total investment is anticipated reach $ 216. billion and the network 120,000 kilometers, says IBISWorld. Even though a big proportion of this investment is dedicated to railways for passenger targeted traffic, the Freight Rail Transport business will advantage as current railways are freed up for freight traffic.

&#13

The Freight Rail Transport industry is expected to generate $ 36.two billion in 2013. More than the 5 years by way of 2013, market income has been expanding 7.5% per year, says IBISWorld. This business is topic to a medium concentration level as the prime 4 players account for about 40.% of business revenue. Rail transportation organizations in China are dominated by 18 railway administrations below the Ministry of Railway, like the Taiyuan, Xi’an and Wuhan Railway Administrations that were established in March 2005.

&#13

The government has announced it will dismantle the original Railway Ministry and set up the China Railway Corporation to run transportation nationwide. This new entity will have the capability to implement reforms to the current rail transport pricing mechanisms, which has the potential to significantly have an effect on the market as freight transport pricing is currently marketplace-oriented.

&#13

Due to investment shortages on railways and the inadequate railway transportation capacity, private capital and foreign investments have been encouraged by the government in current years. The combination of the Ministry of Railway’s function as each government organization and business player, along with the policy of uniform scheduling and pricing, makes investing in the railway industry risky and reasonably unattractive for several private firms. However, as reforms are created in the market (like the transition to a industry-oriented pricing mechanism), non-state-owned players are anticipated to increase in the sector.

&#13

For much more details, pay a visit to IBISWorlds Freight Rail Transport in China sector report page.

&#13

Adhere to IBISWorld on Twitter: https://twitter.com/#!/IBISWorld&#13

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

&#13

IBISWorld Business Report Key Topics

&#13

The Freight Rail Transport sector in China operates railways for the transportation of freight across China. The business comprises state-owned railways as nicely as neighborhood railways (invested and operated by nearby governments) for transferring freight or cargo. Management and operations of railway terminals and station facilities are not included in this market.

&#13

Business Overall performance&#13

Executive Summary&#13

Key External Drivers&#13

Existing Efficiency&#13

Market Outlook&#13

Sector Life Cycle&#13

Goods &amp Markets&#13

Provide Chain&#13

Items &amp Solutions&#13

Major Markets&#13

Globalization &amp Trade&#13

Business Places&#13

Competitive Landscape&#13

Industry Share Concentration&#13

Essential Achievement Elements&#13

Price Structure Benchmarks&#13

Barriers to Entry&#13

Major Firms&#13

Operating Conditions&#13

Capital Intensity&#13

Crucial Statistics&#13

Market Information&#13

Annual Adjust&#13

Essential Ratios

&#13

About IBISWorld Inc.&#13

Recognized as the nations most trusted independent supply of industry and market analysis, IBISWorld offers a complete database of distinctive details and evaluation on each US business. With an comprehensive on-line portfolio, valued for its depth and scope, the business equips clientele with the insight essential to make much better business choices. Headquartered in Los Angeles, IBISWorld serves a variety of business, specialist service and government organizations through more than ten areas worldwide. For a lot more information, check out http://www.ibisworld.com or call 1-800-330-3772.

&#13
&#13
&#13
&#13
&#13

Cancer Diagnostic & Therapy Market – Esophageal, Thyroid & Metastatic Breast Analysis in New Research Report at ReportsnReports.com

Posted on by

Dallas, Texas (PRWEB) July 04, 2013

These reports ”Esophageal Cancer – Pipeline Overview, H1 2013”, ”Thyroid Cancer – Pipeline Overview, H1 2013 and Metastatic Breast Cancer Pipeline Assessment, H1 2013, offer an overview of the indications therapeutic pipeline. These reports provide info on the therapeutic development for Esophageal, Thyroid and Metastatic Breast Cancer, full with the latest updates, and special functions on late-stage and discontinued projects. Reports also overview key players involved in the therapeutic improvement for Esophageal Cancer, Thyroid Cancer and Metastatic Breast Cancer .

&#13

Scope for ”Esophageal Cancer – Pipeline Evaluation, H1 2013”, ”Thyroid Cancer – Pipeline Assessment, H1 2013 and Metastatic Breast Cancer Pipeline Evaluation, H1 2013: &#13

&#13
A snapshot of the global therapeutic scenario for Esophageal Cancer, Thyroid Cancer and Metastatic Breast Cancer.&#13
A overview of the products beneath development by businesses and universities/research institutes primarily based on information derived from company and business-specific sources.&#13
Coverage of goods based on different stages of improvement ranging from discovery till registration stages.&#13
A function on pipeline projects on the basis of monotherapy and combined therapeutics.&#13
Coverage of the Esophageal Cancer, Thyroid Cancer and Metastatic Breast Cancer pipeline on the basis of route of administration and molecule kind.&#13
Essential discontinued pipeline projects.&#13
Most current news and offers relating to the items.

Browse Reports Indivudually:&#13

Esophageal Cancer Pipeline Review, H1 2013: http://www.reportsnreports.com/reports/258378-esophageal-cancer-pipeline-assessment-h1-2013.html

&#13

Thyroid Cancer Pipeline Review, H1 2013: http://www.reportsnreports.com/reports/258404-thyroid-cancer-pipeline-overview-h1-2013.html

&#13

Metastatic Breast Cancer Pipeline Review, H1 2013: http://www.reportsnreports.com/reports/258375-metastatic-breast-cancer-pipeline-overview-h1-2013.html

&#13

Organizations Involved in Esophageal Cancer Therapeutics Development: Bristol-Myers Squibb Business, Shionogi &amp Co., Ltd., Tekmira Pharmaceuticals Corp., Bavarian Nordic A/S, Gilead Sciences, Inc., Novartis AG, Cell Therapeutics, Inc., Takara Bio Inc., Synta Pharmaceuticals Corp., Transgene Biotek Ltd, Proteo, Inc., Supratek Pharma Inc., GANYMED Pharmaceuticals AG, Advantagene, Inc., Merrimack Pharmaceuticals, Inc., Omeros Corporation, BioStar Pharmaceuticals, Inc., Kringle Pharma, Inc., ImmunoFrontier, Inc.

&#13

Firms Involved in Thyroid Cancer Therapeutics Improvement: Bristol-Myers Squibb Organization, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., Sanofi-Aventis, AstraZeneca PLC, Daiichi Sankyo Organization, Ltd, Merck &amp Co., Inc., Emergent BioSolutions Inc., Takeda Pharmaceutical Business Limited, Plexxikon Inc., Reliance Life Sciences Pvt. Ltd., Celltrion, Inc., Bio-Path Holdings, Inc., Novartis AG, Eisai Co., Ltd., Genmab A/S, Sandoz Inc., Exelixis, Inc., Celgene Corporation, Bayer AG, EpiCept Corporation, IMMUNOMEDICS, INC, MethylGene Inc, Bionomics Limited, OXiGENE, Inc., Accentia Biopharmaceuticals, Inc., Pharmacyclics, Inc., Cancer Study Technologies Restricted, Memgen, LLC., Azaya Therapeutics, Inc., Vascular Biogenics Ltd., Globeimmune, Inc., Biovista Inc., AmpliMed Corporation, CureTech Ltd., Genelux Corporation, Trophogen, Inc.

&#13

Firms Involved in Metastatic Breast Cancer Therapeutics Development: Bristol-Myers Squibb Company, Johnson &amp Johnson, F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Biogen Idec Inc., Amgen Inc., Adherex Technologies Inc., AstraZeneca PLC, Eli Lilly and Firm, GlaxoSmithKline plc, Seattle Genetics, Inc., Genentech, Inc., Nektar Therapeutics, Bavarian Nordic A/S, MedImmune LLC, Merck &amp Co., Inc., Celltrion, Inc., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc. and a lot more .

&#13

Motives to buy these reports:

&#13

Recognize and recognize essential and diverse types of therapeutics below development for Esophageal Cancer, Thyroid Cancer and Metastatic Breast Cancer.&#13
Recognize emerging players with potentially strong solution portfolio and design efficient counter-strategies to acquire competitive benefit.&#13
Strategy mergers and acquisitions efficiently by identifying players of the most promising pipeline.&#13
Devise corrective measures for pipeline projects by understanding Esophageal Cancer, Thyroid Cancer and Metastatic Breast Cancer pipeline depth and concentrate of Indication therapeutics.&#13
Develop and style in-licensing and out-licensing techniques by identifying potential partners with the most attractive projects to enhance and expand company possible and scope.&#13
Modify the therapeutic portfolio by identifying discontinued projects and understanding the aspects that drove them from pipeline.

Cancer Diagnostic Testing: Granular Evaluation of the US Market place Supplier Shares and Forecasts for Existing and Emerging Tumor Markers – http://www.reportsnreports.com/reports/255711-cancer-diagnostic-testing-granular-analysis-of-the-us-marketplace-supplier-shares-and-forecasts-for-present-and-emerging-tumor-markers.html: This new report, Competing in the US Cancer Diagnostics Industry, such as supplier shares, as well as test volume and sales forecasts for 40 tumor markers. The DataPack will aid present suppliers and prospective marketplace entrants identify and evaluate emerging opportunities in the US cancer diagnostics market place in the course of the next 5 years, and help market executives in establishing successful business, new item development and marketing and advertising approaches.

&#13

Market place Segmentation Evaluation:&#13

Sales and market place shares of significant suppliers, by individual tumor marker.&#13
5-year test volume and sales forecasts for main tumor markers by market segment, including:&#13
Hospitals&#13
Commercial/Private Laboratories&#13
Doctor Offices/Group Practices&#13
Cancer Clinics

Explore much more reports on Cancer Marketplace @ http://www.reportsnreports.com/tags/cancer-marketplace-analysis.html.

&#13

About US:&#13

ReportsnReports.com is an on the web market investigation reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth research of 5000+ micro markets. Our database involves reports by top publishers from across the globe.

&#13
&#13
&#13
&#13
&#13

Associated Administrator Press Releases

Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld

Posted on by


Los Angeles, CA (PRWEB) May 25, 2013

IBISWorld estimates that revenue for the Cell Therapy industry will grow at an average annual rate of 28.7% to $ 1.0 billion in the five years to 2013, including growth of 17.9% in 2013. From 2002 and 2008, no new cell therapy products were introduced, according to IBISWorld industry analyst Kevin Culbert, causing relatively modest growth during that period. In the years since, however, the Food and Drug Administration (FDA) has approved six new products. This factor contributed to the industry’s fast growth during the five years to 2013.

In 2011, the release of Dendreon’s Provenge contributed to revenue growth of 59.5% during the year. The product got a significant boost when Medicare announced that it would cover the cost of reimbursement. In spite of this, the treatment’s reception was expected to be considerably greater. Slow adoption was partially caused by the treatment’s high sticker price (due to its high cost of development), a factor that has led many doctors to use alternative treatments, Culbert says. Industry operators have spent billions of dollars trying to develop a blockbuster treatment that will yield billions of dollars in return. Wage costs contribute significantly to the Cell Therapy industry s high operational costs. In 2013, for example, wages alone are expected to represent 118.5% of industry revenue, causing the industry to operate at a loss throughout its existence.

During that time, industry operators will benefit from the research and development (R&D) that has taken place over the past five years and the clinical trials that are currently in place. The industry will also benefit from the FDA’s Safety and Innovation Act, which was signed into law in July 2012. The act will accelerate the approval process for drug manufacturers, including regenerative medicine products. In spite of this factor, industry firms are expected to continue operating at a loss over the next five years as vast sums of money are poured into R&D. In addition to Dendreon, current major players include Shire Pharmaceuticals, Organogenesis Inc. and NuVasive Inc.

The Cell Therapy industry has a high level of market share concentration. Given that the industry is in the growth stage of its life cycle and it typically takes a number of years to bring a product to market, there is a large number of smaller companies in the industry that are still in the product development stage and awaiting FDA approval. There are currently only about 40 cell therapy products available on the commercial market, according to the Alliance for Regenerative Medicine’s annual report. Consequently, market share concentration is expected to decrease over the next five years as new products are introduced to the commercial market. For more information, visit IBISWorlds Cell Therapy in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

This industry engineers human tissue, also known as cell therapy or regenerative medicine. Tissue engineering is the use of a combination of cells, engineering and materials methods, and suitable biochemical and chemical factors to improve or replace biological functions. Key functions include repairing or replacing tissues (e.g. bone, cartilage, blood vessels and skin).

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nations most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Find More Administrator Press Releases